<document>

<filing_date>
2020-03-27
</filing_date>

<publication_date>
2020-10-08
</publication_date>

<priority_date>
2019-03-29
</priority_date>

<ipc_classes>
G01N33/564
</ipc_classes>

<assignee>
IMMUNOVIA
</assignee>

<inventors>
WINGREN, CHRISTER
ISINGER-EKSTRAND, Anna
OHLSSON, BÃ¶rje Ola Mattias
</inventors>

<docdb_family_id>
66442928
</docdb_family_id>

<title>
METHODS, ARRAYS AND USES THEREOF FOR DIAGNOSING OR DETECTING AN AUTOIMMUNE DISEASE
</title>

<abstract>
The present invention provides a method for diagnosing or detecting an autoimmune disease in an individual, the method comprising or consisting of the steps of (a) providing a sample obtained from an individual to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarkers selected from the group defined in Table 1(A), Table 1(B), Table 1(C), Table 1(D) and/or Table 1(E) wherein the presence and/or amount in the sample of the one or more biomarker(s) is indicative of an autoimmune disease in the individual. The invention also provides an array and a kit suitable for use in the methods of the invention.
</abstract>

<claims>
1. A method for diagnosing or detecting an autoimmune disease in an individual, the method comprising or consisting of the steps of: a) providing a sample obtained from an individual to be tested; and b) measuring the presence and/or amount in the test sample of one or more biomarkers selected from the group defined in Table 1 (A); wherein the presence and/or amount in the sample of the one or more biomarker(s) selected from the group defined in Table 1 (A) is indicative of an autoimmune disease in the individual.
2. The method according to Claim 1 further comprising or consisting of the steps of: c) providing one or more control samples; and
d) measuring the presence and/or amount in the control sample of the one or more biomarkers measured in step (b); wherein the individual is identified as having an autoimmune disease by comparing the presence and/or amount in the test sample of the one or more biomarkers measured in step (b) with the presence and/or amount in the control samples.
3. The method according to Claim 2 wherein the control samples of step (c) are provided from a healthy individual (negative control) and/or from an individual with an autoimmune disease (positive control).
4. The method according to Claim 2 or 3 wherein the control samples of step (c) are provided from an individual with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS) or systemic vasculitis (SV).
5. The method according to Claim 4 wherein the control samples of step (c) are provided from an individual with systemic lupus erythematosus subtype 1 (SLE-1), systemic lupus erythematosus subtype 2 (SLE-2) or systemic lupus erythematosus subtype 3 (SLE-3).
6. The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of two or more of the biomarkers defined in Table 1 (A), for example, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 of the biomarkers defined in Table 1 (A).
7. The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (A) i .
8. The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (A) i i .
9. The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (A)iii.
10. The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of biomarkers defined in Table 1 (A) i , Table 1 (A) i i and/or Table 1 (A)iii.
1 1. The method according to any one of the preceding claims wherein the autoimmune disease is selected from: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS) or systemic vasculitis (SV).
12. The method according to any one of the preceding claims wherein the one or more biomarker(s) selected from the group defined in Table 1 (A) are biomarkers which are also present in Table 2(A).
13. The method according to any one of the preceding claims wherein the method further comprises measuring the presence and/or amount of one or more of the biomarkers defined in Table 2(A).
14. The method according to any one of the preceding claims, wherein the method further comprises measuring the presence and/or amount of one or more of the biomarkers defined in Table 1 (B).
15. The method according to any one of the preceding claims, wherein the method further comprises measuring the presence and/or amount of one or more of the biomarkers defined in Table 1 (C).
16. The method according to any one of the preceding claims, wherein the method further comprises measuring the presence and/or amount of one or more of the biomarkers defined in Table 1 (D). 17. The method according to any one of the preceding claims, wherein the method further comprises measuring the presence and/or amount of one or more of the biomarkers defined in Table 1 (E).
18. A method for diagnosing or detecting systemic lupus erythematosus in an individual comprising or consisting of the steps of: a) providing one or more sample obtained from an individual with, or suspected of having, an autoimmune disease; and
b) measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in Table 1 (B); wherein the presence and/or amount in the one or more test sample of the one or more biomarker(s) selected from the group defined in Table 1 (B) is indicative of systemic lupus erythematosus.
19. The method according to Claim 18 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (B)i. 20. The method according to Claim 18 or 19 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (B)ii.
21. The method according to any one of Claims 18 to 20 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (B)iii.
22. The method according to any one of Claims 18 to 21 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of biomarkers defined in Table 1 (B)i, Table 1 (B)ii and/or Table 1 (B)iii. 23. The method according to any one of Claims 18 to 22 wherein the one or more biomarker(s) selected from the group defined in Table 1 (B) are biomarkers which are also present in Table 2(B).
24. The method according to any one of Claims 18 to 23 wherein the method further comprises measuring the presence and/or amount of one or more of the biomarkers defined in Table 2(B).
25. The method according to any one of Claims 18 to 24 further comprising or consisting of the steps of: c) providing one or more control sample; and
d) measuring the presence and/or amount in the control sample of the one or more biomarkers measured in step (b); wherein the patient is identified as having systemic lupus erythematosus by comparing the presence and/or amount in the test sample of the one or more biomarkers measured in step (b) with the presence and/or amount in the control samples. 26. A method for diagnosing or detecting rheumatoid arthritis in an individual comprising or consisting of the steps of: a) providing one or more sample obtained from an individual with, or suspected of having, rheumatoid arthritis; and
b) measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in Table 1 (C); wherein the presence and/or amount in the one or more test sample of the one or more biomarker(s) selected from the group defined in Table 1 (C) is indicative of rheumatoid arthritis.
27. The method according to Claim 26 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (C) i . 28. The method according to Claim 26 or 27 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (C)ii.
29. The method according to any one of Claims 26 to 28 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (C)iii.
30. The method according to any one of Claims 26 to 29 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of biomarkers defined in Table 1 (C)i, Table 1 (C)ii and/or Table 1 (C)iii.
31. The method according to any one of Claims 26 to 30 wherein the one or more biomarker(s) selected from the group defined in T able 1 (C) are biomarkers which are also present in Table 2(C).
32. The method according to any one of Claims 26 to 31 wherein the method further comprises measuring the presence and/or amount of one or more of the biomarkers defined in Table 2(C). 33. The method according to any one of Claims 26 to 32 further comprising or consisting of the steps of: c) providing one or more control sample; and
d) measuring the presence and/or amount in the control sample of the one or more biomarkers measured in step (b); wherein the patient is identified as having rheumatoid arthritis by comparing the presence and/or amount in the test sample of the one or more biomarkers measured in step (b) with the presence and/or amount in the control samples.
34. A method for diagnosing or detecting Sjogren's syndrome in an individual comprising or consisting of the steps of: a) providing one or more sample obtained from an individual with, or suspected of having, an autoimmune disease; and
b) measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in Table 1 (D); wherein the presence and/or amount in the one or more test sample of the one or more biomarker(s) selected from the group defined in Table 1 (D) is indicative of Sjogren's syndrome.
35. The method according to Claim 34 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (D)i.
36. The method according to Claim 34 or 35 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (D)ii.
37. The method according to any one of Claims 34 to 36 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (D)iii.
38. The method according to any one of Claims 34 to 37 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of biomarkers defined in Table 1 (D)i, Table 1 (D)ii and/or Table 1 (D)iii. 39. The method according to any one of Claims 34 to 38 wherein the one or more biomarker(s) selected from the group defined in T able 1 (D) are biomarkers which are also present in Table 2(D).
40. The method according to any one of Claims 34 to 39 wherein the method further comprises measuring the presence and/or amount of one or more of the biomarkers defined in Table 2(D).
41. The method according to any one of Claims 34 to 40 further comprising or consisting of the steps of: c) providing one or more control sample; and
d) measuring the presence and/or amount in the control sample of the one or more biomarkers measured in step (b); wherein the patient is identified as having Sjogren's syndrome by comparing the presence and/or amount in the test sample of the one or more biomarkers measured in step (b) with the presence and/or amount in the control samples.
42. A method for diagnosing or detecting systemic vasculitis in an individual comprising or consisting of the steps of: a) providing one or more sample obtained from an individual with, or suspected of having, an autoimmune disease; and
b) measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in Table 1 (E); wherein the presence and/or amount in the one or more test sample of the one or more biomarker(s) selected from the group defined in Table 1 (E) is indicative of systemic vasculitis.
43. The method according to Claim 42 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (E)i.
44. The method according to Claim 42 or 43 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (E)ii.
45. The method according to any one of Claims 42 to 44 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of one or more of the biomarkers defined in Table 1 (E)iii
46. The method according to any one of Claims 42 to 45 wherein step (b) comprises or consists of measuring the presence and/or amount in the test sample of biomarkers defined in Table 1 (E)i, Table 1 (E)ii and/or Table 1 (E)iii. 47. The method according to any one of Claims 42 to 46 wherein the one or more biomarker(s) selected from the group defined in Table 1 (E) are biomarkers which are also present in Table 2(E).
48. The method according to any one of Claims 42 to 47 wherein the method further comprises measuring the presence and/or amount of one or more of the biomarkers defined in Table 2(E).
49. The method according to any one of Claims 42 to 48 further comprising or consisting of the steps of: c) providing one or more control sample; and
d) measuring the presence and/or amount in the control sample of the one or more biomarkers measured in step (b); wherein the patient is identified as having systemic vasculitis by comparing the presence and/or amount in the test sample of the one or more biomarkers measured in step (b) with the presence and/or amount in the control samples.
50. The method according to any one of the preceding claims wherein the method is repeated using a test sample taken from the same individual at a different time period to the previous test sample(s) used.
51. The method according to Claim 50 wherein the method is repeated using a test sample taken between 1 day to 104 weeks to the previous test sample(s) used, for example, between 1 week to 100 weeks, 1 week to 90 weeks, 1 week to 80 weeks, 1 week to 70 weeks, 1 week to 60 weeks, 1 week to 50 weeks, 1 week to 40 weeks, 1 week to 30 weeks, 1 week to 20 weeks, 1 week to 10 weeks, 1 week to 9 weeks, 1 week to 8 weeks, 1 week to 7 weeks, 1 week to 6 weeks, 1 week to 5 weeks, 1 week to 4 weeks, 1 week to 3 weeks, or 1 week to 2 weeks.
52. The method according to Claim 50 or 51 wherein the method is repeated using a test sample taken every period from the group consisting of: 1 day, 2 days, 3 day, 4 days, 5 days, 6 days, 7 days, 10 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, 30 weeks, 35 weeks, 40 weeks, 45 weeks, 50 weeks, 55 weeks, 60 weeks, 65 weeks, 70 weeks, 75 weeks, 80 weeks, 85 weeks, 90 weeks, 95 weeks, 100 weeks, 104, weeks, 105 weeks, 1 10 weeks, 1 15 weeks, 120 weeks, 125 weeks and 130 weeks.
53. The method according to any one of Claims 50 to 52 wherein the method is repeated at least once, for example, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 1 1 times, 12 times, 13 times, 14 times, 15 times, 16 times, 17 times, 18 times, 19 times, 20 times, 21 times, 22 times, 23, 24 times or 25 times.
54. The method according to any one of the preceding claims wherein a diagnosis in a patient of an autoimmune disease is subsequently confirmed using one or more additional diagnostic tests for the autoimmune disease.
55. The method according to any one of the preceding claims wherein step (b) comprises measuring the expression of the protein or polypeptide of the one or more biomarker(s).
56. The method according to Claim 55 wherein step (b) and/or step (d) is performed using one or more first binding agents each capable of binding specifically to a biomarker protein or polypeptide to be measured.
57. The method according to Claim 56 wherein the first binding agent is an antibody or a fragment thereof.
58. The method according to Claim 57 wherein the antibody or fragment thereof is a recombinant antibody or fragment thereof.
59. The method according to Claim 56 or 57 wherein the antibody or fragment thereof is selected from the group consisting of: scFv; Fab; a binding domain of an immunoglobulin molecule.
60. The method according to any one of Claims 56 to 59 wherein the first binding agent is immobilised on a surface.
61. The method according to any one of the preceding claims wherein the one or more biomarker(s) in the test sample is labelled with a directly or indirectly detectable moiety.
62. The method according to Claim 61 wherein the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety; an enzymatic moiety.
63. The method according to Claim 61 or 62 wherein the detectable moiety is biotin.
64. The method according to Claim 63 wherein in step (b) and/or step (d) the biotinylated biomarkers are detected using streptavidin labelled with a detectable moiety selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety; an enzymatic moiety.
65. The method according to Claim 64 wherein the detectable moiety is fluorescent moiety (for example an Alexa Fluor dye, e.g. Alexa 647).
66. The method according to any one of the preceding claims wherein step (b) and/or step (d) is performed using an array.
67. The method according to Claim 66 wherein the array is selected from the group consisting of: macroarray; microarray; nanoarray.
68. The method according to any one of the preceding claims wherein the method comprises:
(i) labelling biomarkers present in the sample with biotin;
(ii) contacting the biotin-labelled proteins with an array comprising a plurality of scFv immobilised at discrete locations on its surface, the scFv having specificity for one or more of the proteins in Table 1 (A), Table 1 (B), Table 1 (C), Table 1 (D) and/or Table 1 (E);
(iii) contacting the biotin-labelled proteins (immobilised on the scFv) with a streptavidin conjugate comprising a fluorescent dye; and
(iv) detecting the presence of the dye at discrete locations on the array surface wherein the expression of the dye on the array surface is indicative of the expression of a biomarker from Table 1 (A), Table 1 (B), Table 1 (C), Table 1 (D) and/or T able 1 (E) in the sample.
69. The method according to any one of the preceding claims wherein step (b) and/or step (d) comprises measuring the expression of a nucleic acid molecule encoding the one or more biomarkers.
70. The method according to Claim 69 wherein the nucleic acid molecule is an mRNA molecule.
71. The method according to Claim 69 wherein the nucleic acid molecule is a DNA molecule, such as a cDNA or ctDNA molecule.
72. The method according Claim 70 or 71 , wherein measuring the expression of the one or more biomarker(s) in step (b) and/or step (d) is performed using a method selected from the group consisting of Southern hybridisation, Northern hybridisation, polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), quantitative real-time PCR (qRT-PCR), nanoarray, microarray, macroarray, autoradiography and in situ hybridisation.
73. The method according to any one of Claims 70 to 72, wherein measuring the expression of the one or more biomarker(s) in step (b) is determined using a DNA microarray.
74. The method according to any one of Claims 70 to 73, wherein measuring the expression of the one or more biomarker(s) in step (b) and/or step (d) is performed using one or more binding moieties, each individually capable of binding selectively to a nucleic acid molecule encoding one of the biomarkers identified in Table 1 (A), Table 1 (B), Table 1 (C), Table 1 (D) and/or Table 1 (E).
75. The method according to Claim 74, wherein the one or more binding moieties each comprise or consist of a nucleic acid molecule.
76. The method according to Claim 74 or 75, wherein the one or more binding moieties each comprise or consist of DNA.
77. The method according to any one of Claims 74 to 76 wherein the one or more binding moieties are 5 to 100 nucleotides in length, for example 15 to 35 nucleotides in length.
78. The method according to any one of Claims 74 to 77 wherein the binding moiety comprises a detectable moiety.
79. The method according to Claim 78 wherein the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety (for example, a radioactive atom); or an enzymatic moiety.
80. The method according to Claim 79 wherein the detectable moiety comprises or consists of a radioactive atom.
81. The method according to Claim 80 wherein the radioactive atom is selected from the group consisting of technetium-99m, iodine-123, iodine-125, iodine-131 , indium-1 1 1 , fluorine-19, carbon-13, nitrogen-15, oxygen-17, phosphorus-32, sulphur-35, deuterium, tritium, rhenium-186, rhenium-188 and yttrium-90.
82. The method according to Claim 79 wherein the detectable moiety of the binding moiety is a fluorescent moiety.
83. The method according to any one of the preceding claims wherein the sample provided in step (a) and/or step (c) is selected from the group consisting of unfractionated blood, plasma, serum, tissue fluid, milk, bile, synovial fluid, and urine.
84. The method according to Claim 83, wherein the sample provided in step (a) and/or step (c) is selected from the group consisting of unfractionated blood, plasma and serum.
85. The method according to Claim 83 or 84, wherein the sample provided in step (a) and/or step (c) is serum.
86. The method according to any one of the preceding claims wherein the predictive accuracy of the method, as determined by an ROC AUC value, is at least 0.50, for example at least 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 0.96, 0.97, 0.98 or at least 0.99.
87. The method according to Claim 86 wherein the predictive accuracy of the method, as determined by an ROC AUC value, is at least 0.70.
88. The method according to any one of the preceding claims wherein, in the event that the individual is diagnosed with an autoimmune disease, the method comprises an additional step of administering to the individual a therapy for said autoimmune disease.
89. The method according to Claim 88 wherein the autoimmune disease therapy is selected from the group consisting of: Nonsteroidal anti-inflammatory drugs (NSAID) such as Ibuprofen and Naproxen; Immune-supressing drugs such as Corticosteroids; synthetic DMARDs (such as Methotrexate, cyclophosphoamide); and Biologicals (such as TNF-inhibitors, IL-inhibitors); and combinations thereof.
90. An array for diagnosing or detecting an autoimmune disease in an individual comprising one or agents suitable for measuring the presence and/or amount of one or more biomarkers selected from the group defined in Table 1 (A), Table 1 (B), Table 1 (C), Table 1 (D), and/or Table 1 (E).
91. An array according to Claim 78 comprising one or more binding agents as defined in any one of Claims 56 to 65 or 74 to 82.
92. An array according to Claim 78 or 79 wherein the one or more binding agents are collectively capable of binding to all of the proteins defined in Table 1 (A), Table 1 (B), Table 1 (C), Table 1 (D), and/or Table 1 (E).
93. Use of one or more biomarkers selected from the group defined in Table 1 (A), Table 1 (B), Table 1 (C), Table 1 (D), or Table 1 (E) as a biomarker for diagnosing or detecting an autoimmune disease in an individual, optionally wherein the autoimmune disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS) or systemic vasculitis (SV).
94. The use according to Claim 81 wherein all of the biomarkers defined in Table 1 (A), Table 1 (B), Table 1 (C), Table 1 (D), and/or Table 1 (E) are used as a biomarker for diagnosing or detecting an autoimmune disease in an individual, optionally wherein the autoimmune disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS) or systemic vasculitis (SV).
95. A kit for diagnosing or detecting an autoimmune disease in an individual comprising: i) one or more first binding agents as defined in any one of Claims 56 to 65 or 74 to 82,
ii) (optionally) instructions for performing the method as defined in any one of Claims 1 to 89.
96. A method of treating an autoimmune disease in an individual comprising the steps of:
(a) diagnosing an individual with an autoimmune disease using a method according to any one of Claims 1 to 89; and
(b) providing the individual with a therapy to treating said autoimmune disease.
97. A method or use substantially as described herein. 98. An array or kit substantially as described herein.
</claims>
</document>
